Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NanoViricides has announced today that a fundamental PCT patent application, on which the nanoviricides technology is based, has resulted in additional issued patents in Australia and the Philippines.
Subscribe to our email newsletter
The Australian and Philippine patents have been allowed with a very broad range of claims to a large number of families of chemical structure compositions, pharmaceutical compositions, methods of making the same, and uses of the same.
NanoViricides holds exclusive, perpetual, worldwide licenses to these technologies for a broad range of antiviral applications and diseases.
These compositions result in self-assembling polymers that we call ‘TheraCour’ polymers (or pi-polymers), and possess significant advantages over the earlier block-copolymer systems, hard nanoparticle systems, as well as liposomal and emulsion systems, that are now advancing in nanomedicines development.
The TheraCour polymers result in polymeric micelles that can be used to encapsulate active pharmaceutical ingredients (APIs) to develop superior drugs where needed. Of greater importance to NanoViricides, they are capable of direct targeting to any desired surface with defined specificity, such as a virus particle.
The current first generation nanoviricides drug candidates have achieved very high levels of effectiveness only by employing the specific targeting ability of the TheraCour polymer systems.
These first generation drugs did not require encapsulation of any additional APIs to achieve their high levels of effectiveness. The company believes this has simplified the drug approval process for us, because the specifically targeted nanoviricide polymer we make is itself the drug in these cases.
In addition, with this technology, the company has the ability to develop drugs against intractable viral diseases wherein very little virus may be present in circulation. In such cases, the company can employ the approach of encapsulating multiple antiviral APIs that act by orthogonal mechanisms, and deliver the payload specifically to infected cells by using ligands that bind preferentially to infected cells.
In addition to this basic PCT application that covers the pi-polymer structure itself, another PCT application that discloses making antiviral agents from the TheraCour family of polymers and such structures is in various stages of prosecution in several countries, and has already issued in at least seven countries and regions.
The original ‘pi-polymer international application was filed under the Patent Cooperation Treaty system in 2006. Several other patents have already been granted previously in this patent family in various countries and regions, including Canada, Europe, Israel, ARIPO, China, HongKong, Japan, Mexico, New Zealand, OAPI, Vietnam and South Africa, and the USA. Prosecution in several other countries continues.
NanoViricides holds exclusive, worldwide, perpetual, licenses from TheraCour Pharma to these technologies and patents for a broad range of antiviral applications and diseases that include all Influenzas including Asian Bird Flu virus, human immunodeficiency virus, Hepatitis B virus, Hepatitis C virus, Herpes Simplex Virus, Dengue viruses, Rabies virus, Ebola/Marburg viruses, Japanese Encephalitis virus, as well as viruses causing viral Conjunctivitis (a disease of the eye) and ocular herpes.